Rhabdomyosarcomas constitute a collection of childhood malignancies thought to arise as a consequence of regulatory disruption of skeletal muscle progenitor cell growth and dierentiation. Our understanding of the pathogenesis of this neoplasm has recently bene®ted from the study of normal and malignant myogenic cells in vitro, facilitating the identi®cation of diagnostic cytogenetic markers and the elucidation of mechanisms by which myogenesis is regulated. It is now appreciated that the delicate balance between proliferation and dierentiation, mutually exclusive yet intimately associated processes, is normally controlled in large part through the action of a multitude of growth factors, whose signals are interpreted by members of the MyoD family of helix ± loop ± helix proteins, and key regulatory cell cycle factors. The latter have proven to be frequent targets of mutational events that subvert myogenesis and promote the development of rhabdomyosarcoma. Although signi®cant progress has been made in the treatment of rhabdomyosarcoma, patients presenting with metastatic disease or certain high risk features are still faced with a dismal prognosis. Only now are genetically engineered mouse models becoming available that are certain to provide fresh insights into the molecular/genetic pathways by which rhabdomyosarcomas arise and progress, and to suggest novel avenues of therapeutic opportunity.
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Rhabdomyosarcoma ± clinical considerations
Rhabdomyosarcoma (RMS), the most common softtissue sarcoma in children, was initially described as a separate entity by Weber in 1854. Almost a century later a large descriptive series of RMS tumors was published (Stout, 1946) . RMS falls into the broader category of small blue round cell tumors of childhood, and histologically resembles normal fetal skeletal muscle. Therefore, the diagnosis of RMS is based on the identi®cation of speci®c features of the skeletal muscle lineage. This consists of the identi®cation of cross-striations characteristic of skeletal muscle, either by light or electron microscopy. In addition, immunohistochemical detection of muscle-speci®c protein expression, including staining for a-actin, myosin heavy chain, desmin, myoglobin, Z-band protein and MyoD, is useful in con®rming the diagnosis.
The two major categories of RMS are of embryonal and alveolar histologies, and are distinguishable based on both light microscopic evaluation (Horn and Enterline, 1958) and the detection of distinct characteristic molecular/genetic markers (Scrable et al., 1989) . Embryonal RMS neoplasms are typically comprised of spindle shaped cells, with a stromal rich appearance. Two major variants of embryonal histology are the botryoid and leiomyomatous variants. Botryoid (grape-like) tumors occur almost exclusively in the bladder or vagina of infants and young children, or from the nasopharynx in slightly older children. The characteristic histology of this embryonal variant is a dense tumor cell layer under an epithelium (cambium layer). The leiomyomatous or spindle cell variant arises frequently in the paratesticular region, but can be found at a variety of sites. Histologically, these tumors consist of characteristic elongated spindle cells in a storiform pattern with abundant collagen between tumor cells, or in bundles with low collagen content. These variant embryonal tumors are associated with limited stage disease and a favorable prognosis. Embryonal tumors are characterized by loss of heterozygosity (LOH) at the 11p15 locus, a region harboring the insulin-like growth factor 2 (IGF2) gene and associated with loss of maternal-and duplication of paternal-chromosomal material. In general, embryonal tumors tend to occur in the younger age group and occur more frequently in the head and neck region and less frequently in the extremities. Approximately two thirds of all RMS are of embryonal histology.
Alveolar RMS is typically comprised of small round densely packed cells, arranged around spaces resembling pulmonary alveoli. A solid variant form of alveolar RMS has been identi®ed, which consists of small round densely packed cells without the characteristic aveolar spaces. There does not appear to be any prognostic signi®cance of the solid alveolar variant. Alveolar tumors harbor a distinguishing chromosomal translocation marker, typically t(2;13)(q35;q14). The cloning and identi®cation of characteristic translocations associated with alveolar histology have permitted the application of reverse transcriptase ± PCR in the diagnostic evaluation of these tumors. This application of molecular diagnosis allows for a precise de®nition of alveolar tumors and excellent correlation with the histological diagnosis in greater than 95% of cases. In contrast to the embryonal type, alveolar RMS tends to occur in the older age group and is more frequently seen in extremity lesions. Pleomorphic RMS is currently rarely diagnosed and is characterized by large aggregates of anaplastic cells. It is often diagnosed in adults and its relationship to pediatric RMS is unclear.
Among extracranial solid tumors of childhood, RMS is the third most common, after neuroblastoma and Wilms' tumor. More than 50% of cases occur in children 5 years or younger, with a second, smaller incidence peak occurring in early adolescence. Approximately 200 new cases of RMS are diagnosed yearly in the US. There is a slight male preponderance (1.4 times more common than in females). Unlike Ewing's sarcoma that has a striking predilection for Caucasians, there are no signi®cant dierences in the incidence of these tumors among races or ethnic groups. Two clinical staging systems are currently employed for RMS. The widely used clinical grouping strategy of the Intergroup Rhabdomyosarcoma Study (IRS) Committee de®nes four major disease categories based on the amount of tumor remaining following the initial surgery, and the extent of tumor dissemination at diagnosis (Maurer et al., 1988) . Additionally, the Tumor-Nodes-Metastasis (TNM) system has been implemented, which relies on staging criteria such as primary tumor site and size, involvement of adjacent structures and regional lymph nodes, and presence of distant metastasis (Mandell, 1993) .
The overwhelming majority of RMS tumors appear to be sporadic with no known predisposing factors. However, the now well described Li-Fraumeni syndrome, clearly associated with p53 germline mutations, was initially identi®ed from a RMS as the index case and includes these tumors along with other soft-tissue sarcomas (Li and Fraumeni, 1969) . In a recent study of 33 sporadic cases of RMS, it was found that while no germline mutations were identi®ed in children presenting over the age of 3 years, three of ten cases in children presenting at 3 years or younger did harbor p53 germline mutations (Dagher and Helman, 1999) . This study has signi®cant implications regarding the counseling and treatment of very young children presenting with RMS, and suggests such patients should be referred to a genetic counseling team for consideration of determination of p53 status. Of further interest is the association of RMS with the Beckwith-Wiedemann syndrome, a fetal overgrowth disorder demonstrating abnormalities at the 11p15 locus, noted above to experience LOH in most embryonal tumors, and to which the IGF2 gene maps.
Cytogenetic de®nition of rhabdomyosarcoma
A number of molecular/genetic lesions have now been associated with human RMS (summarized in Table 1 ). Embryonal and alveolar RMS can be distinguished cytogenetically (Scrable et al., 1989) . Approximately 90% of alveolar RMS carry a characteristic chromosomal translocation juxtaposing the 5' DNA-binding domains (paired box and homeodomain) of PAX, a member of the Paired Box transcription factor family, to the transactivation domain at the 3' portion of FKHR, a member of the forkhead/HNF-3 transcription factor family Galili et al., 1993; Davis et al., 1994) . The majority of these structural rearrangements translocate the PAX3 gene at 2q35 to the FKHR gene at 13q14 (t(2;13)(q35;q14)); less frequently, a t(1;3)(q36;q14) translocation fuses PAX7 to FKHR. The PAX3-FKHR chimera is a more potent transcriptional activator than wild type pax3 (Fredericks et al., 1995) , and presumably disrupts the normal regulation of target genes downstream of PAX3. Recently, it was reported that it is the PAX3 homeodomain recognition helix, and not the pairedbox DNA binding domain, that is required for transformation by the PAX3-FKHR chimera (Lam et al., 1999) . The involvement of PAX3 in RMS is strongly reinforced by its demonstrated role in skeletal muscle development, as discussed below.
In contrast to alveolar neoplasms, embryonal RMS rarely bear this genetic lesion. In embryonal tumors where the above noted translocations are not seen, LOH at the 11p15 locus is almost uniformly identi®ed (Besnard-GueÂ rin et al., 1996; Visser et al., 1997) . This region of the short arm of chromosome 11 contains a number of imprinted genes implicated in oncogenesis, including H19, IGF2 and p57
KIP2
(reviewed by Feinberg, 1999) ; however, the relevant genetic target of this putative loss-of-function mutation has yet to be identi®ed. The 11p15 region is imprinted in normal tissue, with only the paternal allele being transcribed. However, unlike normal tissue, RMS tumors have been found to demonstrate loss of imprinting (LOI), coincident with active transcription from both maternal and paternal alleles. This LOI can lead to a twofold gene dosage eect, and may contribute to the characteristic overexpression of IGF2 observed in these tumors (Zhan et al., 1994) . LOH studies have Barr et al., 1993; Galili et al., 1993 Davis et al., 1994 Besnard-GueÂ rin et al., 1996 Visser et al., 1997 Stratton et al., 1990 Mulligan et al., 1990; Felix et al., 1992 El-Badry et al., 1990 Zhan et al., 1994 Meddeb et al., 1996 Keleti et al., 1996; Fiddler et al., 1996 Khatib et al., 1993 Knudsen et al., 1998 Ferracini et al., 1996 Garson et al., 1986 Mitani et al., 1986; Bayani et al., 1995 Weber-Hall et al., 1996 Smith et al., 1998 Iolascon et al., 1996 Schweigerer et al., 1987 De Giovanni et al., 1995 Chardin et al., 1985 Stratton et al., 1989 *Denotes alterations seen commonly in both RMS cell lines and tumor tissue; other lesions occur occasionally, and/or have been infrequently reported. LOH, loss of heterozygosity; LOI, loss of imprinting also suggested the existence of putative RMSassociated tumor suppressor genes residing at 11q and 16q (Loh et al., 1992; Visser et al., 1997) .
Other highly consequential genetic alterations have been associated with rhabdomyosarcomagenesis. Mutation in the p53 gene is now widely considered to be the most common genetic lesion in human cancers, and RMS is no exception (Stratton et al., 1990; Mulligan et al., 1990; Felix et al., 1992) . Mutations in p53 have been detected in nearly 50% of RMS cases examined. Families predisposed to this cancer often harbor germline missense mutations in p53 (Malkin et al., 1990; Srivastava et al., 1990) ; in such cases, subsequent allelic loss at the p53 locus on chromosome 17 is highly prevalent. Interestingly, wild type p53 inhibits transcription of the IGF2 gene (Zhang et al., 1996 (Zhang et al., , 1998 , a ®nding that could help explain its penchant for overexpression in RMS and some other tumors. Nmyc has been found to be ampli®ed in both embryonal and alveolar RMS primary tumors and cell lines (Garson et al., 1986; Mitani et al., 1986; Bayani et al., 1995) . Moreover, microarray analysis demonstrated that N-myc was consistently highly expressed in alveolar RMS cell lines (Khan et al., 1998) . Activated forms of N-ras and K-ras are among the most frequent oncogene abnormalities observed in RMS tumors (see review by Dias et al., 1994) . In one study, 35% of embryonal tumors carried activating mutations of either N-or K-ras (Stratton et al., 1989; Wexler and Helman, 1994) . Activated ras has been shown to block myogenic dierentiation by down-regulating myogenic factors such as MyoD and myogenin (Lassar et al., 1989; Konieczny et al., 1989) . The chromosomal region at 12q13-15, encoding factors of regulatory signi®cance such as GLI, MDM2 and CDK4 , is frequently ampli®ed in human sarcomas, including some RMS cell lines (Khatib et al., 1993; Berner et al., 1996; Meddeb et al., 1996) . The hepatocyte growth factor/scatter factor (HGF/SF) receptor proto-oncogene, c-MET, has been reported to be overexpressed and occasionally ampli®ed in human RMS tumors and cell lines (Ferracini et al., 1996) , the signi®cance of which will be discussed later.
Lessons from skeletal muscle development
A short developmental primer RMS arises as a consequence of regulatory disruption of the growth and dierentiation of myogenic precursor cells. These two cellular processes are mutually exclusive, yet intimately associated one with the other. It follows that delineation of the pathways that control myogenic dierentiation and growth will provide relevant clues to the origin of RMS. During embryogenesis, studied predominantly in chicken and mouse, all skeletal muscle is derived from two distinct populations of primitive mesodermal cells residing within the dermomyotome portion of the somite. The medial lip of the dermomyotome gives rise locally to the epaxial musculature, including deep muscles of the back, while cells from the lateral lip must migrate before forming the hypaxial musculature, including muscles of the tongue, diaphragm and limb (see reviews by Buckingham, 1992; Christ and Ordahl, 1995) . Commitment of somitic cells to the myoblast lineage is accompanied by expression of members of the MyoD family of myogenic regulators, which includes MyoD, myogenin, Myf-5 and Myf-6. Our understanding of skeletal muscle development has been substantially enhanced by the creation and analysis of mice carrying null mutations in one or more of these myogenic regulators (reviewed by Weintraub, 1993; Arnold and Braun, 1996) . For example, it is now clear that in mice MyoD and Myf-5 share redundant functions for generating myoblasts, but expression of either one or the other is essential for skeletal muscle development (Rudnicki et al., 1993) . In contrast, mice with null mutations in myogenin make myoblasts, but they fail to dierentiate (Hasty et al., 1993; Nabeshima et al., 1993) . Myoblasts emigrating from the medial dermomyotome defer activation of these myogenic HLH genes until after reaching their ®nal destination (Dias et al., 1994; Arnold and Braun, 1996) . MyoD family members can homodimerize, and more efficiently form heterodimers with other HLH proteins, such as the E2A gene products E12 and E47. Musclespeci®c genes can be transcriptionally activated, for example, through the binding of these heterodimers at promoter binding sites termed E-boxes (reviewed by Olson, 1992; Dias et al., 1994) .
The patched/pax/met connection
The induction of somitic myogenesis requires wnt-1 and sonic hedgehog (shh) signaling from adjacent neural tube and notochord, respectively, which together induce downstream expression of pax3 and pax7 in the condensing somite (MuÈ nsterberg et al., 1995; Stern et al., 1995; Maroto et al., 1997) . The importance of pax3 in skeletal muscle development is appreciated by the lack of limb muscles in the pax3-de®cient spontaneous mouse mutant, Splotch (Bober et al., 1994; Goulding et al., 1994) , and the association of limb muscle hypoplasia with PAX3 haploinsuciency in patients with Waardenburg syndrome (reviewed by Mansouri, 1998) . Upstream of pax3, signaling through wnt and shh are negatively regulated by the shh receptor patched (ptc), a putative tumor suppressor (reviewed by Ingham, 1998) . It is therefore notable that Hahn et al., (1998) reported that 9% of 6 ± 13 week-old mice bearing only one functional ptc allele developed neoplasms morphologically resembling human embryonal RMS. Molecular analysis revealed that these RMS tumors overexpressed gli-1, a zinc ®nger transcription factor positively regulated by smoothened (smo), a component of the shh receptor complex normally repressed by wild type levels of ptc. This was signi®cant also because GLI is part of a cluster of genes at 12q13 ± 15 frequently coampli®ed in human sarcomas, including CDK4 and MDM2. IGF2 was upregulated in these murine tumors as well.
Prior to emigration, migratory precursor cells within the lateral dermomyotome destined to produce the tongue, diaphragm and limb express both pax3 and c-MET. The c-met proto-oncogene encodes a receptor tyrosine kinase (RTK) that mediates the multifunctional and potentially oncogenic activities of HGF/SF, including stimulation of growth, extracellular matrix degradation, angiogenesis, and motility or`scatter' (reviewed by Jeers et al., 1996; Matsumoto and Nakamura, 1996) . In fact, the requisite epithelialmesechymal conversion and delamination experienced by somitic migratory precursor cells prior to emigration, functionally analogous to scatter behavior exhibited in vitro by cells of the MDCK kidney line in response to HGF/SF, is thought to be mediated by Met. A number of observations suggest that c-met is a downstream target of pax3, already clearly implicated in human alveolar RMS. As in pax3-de®cient Splotch mice, myogenic precursor cells in c-met-de®cient mice cannot populate the limbs, and limb and diaphragm muscles fail to develop (Bober et al., 1994; Goulding et al., 1994; Bladt et al., 1995; Maina et al., 1996) . Expression of c-met in lateral dermomyotome is downregulated in Splotch mice (Daston et al., 1996; Epstein et al., 1996; Yang et al., 1996) , although c-metindependent muscular anomalies have been described in this mutant as well (Dietrich et al., 1999) . Ectopic application of exogenous HGF/SF induces the emigration of Pax3-expressing myogenic cells (Brand-Saberi et al., 1996) . Moreover, the c-met promoter contains putative Pax3 binding sites (Epstein et al., 1996; Phelan and Loeken, 1998) . c-MET has been shown to be upregulated in human alveolar RMS expressing the PAX3-FKHR fusion protein (Epstein et al., 1996; Ferracini et al., 1996; Ginsberg et al., 1998) ; however, c-MET expression can reach comparable levels in a smaller fraction of human embryonal RMS lacking the t(2;13)(q35;q14) translocation as well (Ferracini et al., 1996; Ginsberg et al., 1998) . These ®ndings implicate c-MET in human rhabdomyosarcomagenesis. This conclusion is strongly supported by the consequences of constitutive activation of c-met in HGF/SF transgenic mice, about 4% of which develop RMS (Takayama et al., 1997) . Autocrine activation of Met kinase was detected in these RMS, one of which carried an ampli®ed endogenous c-met gene. c-MET ampli®cation has also been reported in some human RMS tumors (Ferracini et al., 1996) .
The ins and outs of the cell cycle
Scratching the surface ± growth factors in regeneration and tumorigenesis Rhabdomyosarcomas are thought to arise predominantly from committed skeletal muscle precursor cells. A credible candidate for such a precursor in postnatal skeletal muscle is the satellite cell ± a quiescent myogenic stem cell situated between the sarcolemma and basal lamina of muscle ®bers. Satellite cells are responsible for the regeneration of skeletal muscle in response to various types of injury, a process which recapitulates the developmental myogenic pathway. Under normal circumstances, injury activates quiescent satellite cells, coaxing them out of G 0 and into the cell cycle. Following a proliferation phase, newly activated satellite cells simultaneously exit the cell cycle and dierentiate, then fuse with adjacent ®bers in uninjured muscle and form multinucleated myotubes, eectively replacing the damaged ®bers (reviewed by Bischo, 1994) . The availability of myogenic cell lines, single muscle ®ber and primary satellite cell cultures has permitted a hard experimental look at factors regulating the entry and exit from the cell cycle of myogenic precursor cells. This, in turn, has led to new insights into mechanisms by which such regulation is disrupted in rhabdomyosarcomagenesis.
It is now appreciated that myogenic precursor cell proliferation and dierentiation are regulated in large part through the action of a variety of external growth factors, including HGF/SF, FGFs, IGFs, plateletderived growth factor (PDGF) and transforming growth factor b (TGFb) (reviewed by Husmann et al., 1996; Maione and Amati, 1997) . Indeed, analysis of FGF6 (7/7) mutant mice showed that this FGF was absolutely required for normal skeletal muscle regeneration (Floss et al., 1997) . These factors stimulate satellite cell proliferation to varying degrees, and most simultaneously inhibit terminal dierentiation as well. The exceptions are the IGFs, particularly IGF2, which typically promote satellite cell dierentiation; however, the in¯uence of IGF2 on dierentiation may be countered by speci®c FGFs (Rosenthal et al., 1991) . It has been shown that factor availability is necessary but not sucient for initiation of regeneration; quiescent satellite cells cannot respond to most factors because they do not possess the appropriate receptors (reviewed by Bischo, 1994) . However, recent studies have identi®ed HGF/SF as uniquely able to initiate G 0 and G 1 transition of quiescent satellite cells, which have also been shown to express c-met as a diagnostic marker Cornelison and Wold, 1997; Anastasi et al., 1997; Gal-Levi et al., 1998; Tatsumi et al., 1998) . In contrast, for example, FGFR is not expressed in satellite cells until after entry into the cell cycle (Johnson and Allen, 1995) . After a period of proliferation, downregulation of receptors such as Met and FGFR would normally accompany the induction of terminal dierentiation.
From these and subsequent studies, it is clear that growth factor-RTK signaling constitutes a highly sensitive target for cell cycle dysregulation associated with RMS. For example: c-MET ampli®cation and overexpression has been detected in RMS, as discussed above (Ferracini et al., 1996; Takayama et al., 1997) ; basic ®broblast growth factor (bFGF)-FGF receptor (FGFR) autocrine signaling has been reported in human RMS cells (Schweigerer et al., 1987; De Giovanni et al., 1995) ; and IGF2 is consistently overexpressed in both embryonal and alveolar RMS, where it can induce autocrine signaling through the IGF1 RTK, and cooperate with PAX3-FKHR (ElBadry et al., 1990; Minniti et al., 1994; Wang et al., 1998) . Insights gained through analysis of satellite cells and skeletal muscle regeneration provide a rational hypothesis for how constitutive activation of speci®c growth factor receptor signaling pathways can disrupt the delicate balance between proliferation and differentiation, creating an expanded pool of cycling myogenic progenitors that become targets of further mutagenesis and seeds of future RMS. Growth factor signals at the cell surface are interpreted by myogenic and cell cycle proteins, which we consider below.
Digging deeper ± pRB and p53 at the crossroads
The regulatory convergence of myoblast proliferation and dierentiation again becomes apparent upon examination of select tumor suppressors poised at the Rhabdomyosarcoma ± working out the pathways G Merlino and LJ Helman heart of the cell cycle, including the retinoblastoma (RB) protein (pRB) and p53. pRB is a suppressor of cell proliferation; its phosphorylated form dictates the cycling state of a cell (reviewed by Hinds, 1995; Weinberg, 1996) . In the unphosphorylated state pRB engages the E2F protein family, which would otherwise transcriptionally activate a number of cell cycle genes required for G 1 /S transition. pRB can be phosphorylated by G 1 cyclin-dependent kinases (CDK4 and CDK6) in concert with speci®c regulatory G 1 cyclins (such as cyclin D1), thereby releasing E2F and propelling the cell through the restriction point of the cycle (reviewed by Sherr and Roberts, 1999) . One step further upstream, the ability of CDK4/6 to phosphorylate pRB is modulated through direct association with cyclin-dependent kinase inhibitors such as the tumor suppressors p16
INK4a and p21
CIP1
. The importance of RB and associated pathways in myogenic dierentiation was demonstrated by the discoveries that: pRB binds directly with MyoD and other myogenic basic HLH members; pRB is required for MyoD to inhibit cell growth; and that inactivation of pRB disrupts normal myogenesis, and even permits terminally dierentiated cells to reenter the cell cycle (Gu et al., 1993; Thorburn et al., 1993; Novitch et al., 1996) . In addition, forced expression of the E2F family member E2F-1 interferes with myogenic dierentiation , and constitutive expression of cyclin D1 blocks MyoD-dependent transactivation of muscle-speci®c promoters via a CDK-dependent mechanism (Rao et al., 1994; Skapek et al., 1995) . However, G 1 cyclin-CDK activity inhibits the skeletal muscle dierentiation program by distinct pathways, either dependent on, or independent of, pRBhyperphosphorylation (Skapek et al., 1996) . The latter may be realized through a direct CDK4-MyoD interaction (Zhang et al., 1999) .
Despite the obvious connection between pRB/cyclin-CDK activity and myogenesis, data implicating these proteins in rhabdomyosarcomagenesis has not been compelling. A major problem in this regard is the relative dearth of human RMS tissue samples available for molecular analysis. In those RMS samples that have been analysed, the structure and expression of the RB gene itself appear to be normal (Stratton et al., 1989; De Chiara et al., 1993) . Moreover, the occurrence of RMS as a secondary malignancy following retinoblastoma remains controversial (Dickman et al., 1997). However, a number of molecular studies utilizing available human RMS tissue and cell lines have suggested the involvement of factors upstream of RB. When exposed to mitogen-poor dierentiation-inducing media, cells from the RMS line RD maintained pRB in the hyperphosphorylated state, and contained greatly elevated levels of the G 1 cyclins and CDK2 and CDK4 relative to normal human myoblasts, explaining in part their failure to growth arrest or dierentiate under these conditions (Knudsen et al., 1998) . The CDK4 gene, part of an amplicon frequently associated with sarcomas, was found to be ampli®ed in one human RMS cell line, RMS13 (Khatib et al., 1993; Berner et al., 1996) . Microarray analysis of multiple alveolar RMS cell lines revealed CDK4 to be one of the few consistently expressed genes relative to a reference cell line (Khan et al., 1998) . Using PCR analysis, Iolascon et al. (1996) reported that the human p16
INK4a gene experienced homozygous deletion in several RMS cell lines and primary tumors. Taken together, these data raise the possibility that in RMS development the function of speci®c elements in the pRB-associated cyclin-CDK pathways may have been subverted to prevent growth arrest and/or block dierentiation of myogenic precursor cells.
As alluded to above, mutations in p53 are relatively common in human neoplasms, including RMS (Stratton et al., 1990; Mulligan et al., 1990; Felix et al., 1992) . The signi®cance of p53 as a suppressor of tumorigenesis is highlighted by the phenotypic consequences of its inactivation in genetically engineered mouse models (reviewed by Attardi and Jacks, 1999) . Mice carrying null mutations in both p53 alleles exhibit a constellation of neoplasms, the majority being lymphomas; remarkably, however, p53 heterozygotes over a year old develop mostly sarcomas, 19% of which are RMS (Harvey et al., 1993; L Donehower, personal communication) . p53 is a potent sequencespeci®c transcription factor that plays a pivotal role in the regulation of genes responsible for stress-induced growth arrest and apoptosis (reviewed by el-Deiry, 1998; Prives, 1998; Sherr, 1998 ). The precise cellular response to p53 depends on the status of RB, functionally linking the two pathways. In RB-deficient cells, the G 1 checkpoint is circumvented and p53 promotes apoptosis, while in cells possessing wild type RB, p53 can induce G 1 checkpoint arrest through pRB by transcriptionally activating the CDK4/6 inhibitor p21 CIP1 (Ko and Prives, 1996) . RB and p53 are also associated in that each pathway is strictly regulated by distinct gene products, p16
INK4a and p19 ARF , encoded at the same genetic locus (INK4a/ ARF) (reviewed by Chin et al., 1998) . Although p19 ARF abrogates the ability of MDM2 to negatively regulate p53 activity, it has yet to be directly implicated as an RMS tumor suppressor; in fact, ARF-de®cient mice fail to develop RMS (Kamijo et al., 1999) . Recently, another link between the RB and p53 pathways was forged by the ®nding that increased p16
INK4a expression induced p21 CIP1 through a post-transcriptional mechanism in osteosarcoma cells (Mitra et al., 1999) . Interestingly, mice harboring a transgene encoding the SV40 T-antigen, a potent viral oncogene capable of simultaneously inactivating both p53 and pRB (reviewed by Van Dyke, 1994) , develop RMS at a signi®cantly higher incidence and a much shorter latency, oering credible evidence for the participation of both pathways in the formation of RMS (Teitz et al., 1993;  Table 2 ).
Regulation of p53 activity is stringent and occurs at multiple levels. A critical component of this delicate regulatory network is the oncoprotein MDM2, which controls p53 function through a negative feedback loop (reviewed by Lozano and Montes de Oca Luna, 1998) . Although normally short-lived, p53 is stabilized in response to DNA damage and other forms of stress. The resulting accumulation of p53 triggers activation of its various downstream targets, including the MDM2 gene itself. MDM2 then inhibits p53 activity by binding to, and thereby concealing, its activation domain, and by targeting p53 for ubiquitinationmediated proteasomal degradation Haupt et al., 1997; Kubbutat et al., 1997) . The MDM2 gene, part of the aforementioned amplicon at 12q13 ± 15, is frequently overexpressed and ampli®ed in human sarcomas (Oliner et al., 1992; Leach et al., 1993) , including RMS (Meddeb et al., 1996; Keleti et al., 1996; Fiddler et al., 1996) . Signi®cantly, RMS and other sarcomas demonstrate either MDM2 overexpression or p53 mutations, but not both, indicating that these genetic lesions are redundant. The functional relationship between these two is dramatically corroborated by the ®nding that p53 de®ciency rescues the lethality observed in MDM2 null embryos (Montes de Oca Luna et al., 1995; Jones et al., 1995) . However, forced MDM2 overexpression induced sarcomas in transgenic mice irrespective of the presence of functional p53, providing genetic proof for the existence of a p53-independent MDM2 pathway in sarcomagenesis (Jones et al., 1998) . In this regard, the relevance of MDM2 in RMS development is evidenced by the ®nding that MDM2 ampli®cation and overexpression inhibits MyoD function, thereby abrogating myogenesis (Fiddler et al., 1996) . However, this eect of MDM2 on myogenesis may more directly relate to its ability to interact physically with, and functionally inhibit MyoD-associated growth control by, the pRB protein (Xiao et al., 1995) .
The role of p21 CIP1 in myogenesis and RMS formation, and its precise relationship with p53, appear to be complex. Deletion of p21 was not able to substitute for p53 de®ciency in the rescue of the MDM2 null embryonic lethality, described above (Montes de Oca Luna et al., 1997). Moreover, although the p21 CIP1 gene is transcriptionally activated by p53 (el-Deiry et al., 1993), p21 CIP1 is also upregulated during myogenic dierentiation by a p53-independent mechanism thought to involve MyoDmediated transactivation (Parker et al., 1995; Guo et al., 1995; Halevy et al., 1995; Missero et al., 1995) . It has also been shown that p21 CIP1 is poorly expressed in RMS cells lines, concomitant with both MyoD and p53 inactivity, and failure to G 1 arrest (Otten et al., 1997) . Forced overexpression of human p21 CIP1 in RMS cells induced their accumulation in G 1 . Taken together, these data suggest that p21 CIP1 helps regulate myogenic cell growth and dierentiation through its position at the nexus of the p53 and myogenic basic HLH pathways, and that RMS arises in association with the disruption of both. However, p21 CIP1 gene mutations are not common in RMS neoplasms, and mice with homozygous null mutations in p21 CIP1 fail to exhibit an enhanced incidence of RMS or any other spontaneous tumor (Deng et al., 1995) . These ®ndings could be explained by the existence of alternative downstream targets of these growth and dierentiation pathways that are distinct from, yet functionally analogous to, p21
. Using a genetic screen for loci able to inhibit RMS dierentiation, a new myogenic regulatory factor was identi®ed, ATR, that may have profound implications in regard to mechanisms associated with RMS development . ATR is the mammalian homolog of the yeast rad3 gene, and is related to the human ataxia telangiectasia mutated (ATM) gene; both are nuclear factors with phosphatidylinositol 3-kinase-related activity (Keegan et al., 1996) . When overexpressed in myoblasts ATR inhibits MyoD-dependent dierentiation, and induces aberrant centrosome ampli®cation, aneuploidy, and loss of girradiation-induced G 1 arrest. This constellation of phenotypes is reminiscent of those observed in p53-de®cient cells, raising the possibility that ATR disrupts normal p53 function. A role for ATR in tumorigenesis is further suggested by the enhanced DNA copy number at chromosome 3q in a variety of human tumors, including RMS (Weber-Hall et al., 1996) .
Concluding remarks
Many salient clues concerning the events surrounding rhabdomyosarcomagenesis have been garnered from the in vitro analysis of myoblast development and malignant cell lines. Critical insights have emerged concerning the intricate relationship between proteins controlling the cell cycle, such as pRB, p53, ATR, CDKs and their inhibitors, and those regulating myogenic dierentiation, such as MyoD family members. Genetically engineered mouse models, uniquely valuable for delineating molecular/genetic pathways associated with oncogenesis and evaluating previously unexplored therapeutic prospects, are rare for RMS. Nevertheless, the few models that do exist, although not yet fully exploited, demonstrate the power of this approach ( Table 2 ). The tumors arising in mice carrying a single functional p53 gene serve to corroborate suspicions concerning the role of this pivotal transcription factor in RMS (Harvey et al., 1993) . Moreover, the dramatic enhancement in RMS incidence witnessed upon SV40 T-antigen transgenemediated inactivation of both p53 and pRB (Teitz et al., 1993) , constitutes strong support of the notion that when subverted, these pathways conspire to induce RMS through a potently synergistic mechanism. The appearance of RMS in mice with ptc haploinsuciency reminds us that key developmental regulators are also eective targets for mutagenic events disrupting myoblast function (Hahn et al., 1998) . Finally, it is noteworthy that HGF/SF, discovered to be singularly eective at encouraging quiescent satellite cells to enter the cell cycle while discouraging their programmed exit, can incite the emergence of this neoplasm as well (Takayama et al., 1997) . RMS mouse modeling is currently in its infancy; indeed, to date RMS have been induced in genetically engineered mice more as an experimental byproduct than by actual design. However, what is available can be employed as the foundation on which to construct vastly improved mouse models in the near future.
